Evome Medical Technologies (EVMT) Q3 2024 earnings summary

Executive summary

• Generated $10.0 million in revenue for Q3 2024, with $5.8 million from core business Biodex.

• Achieved $424,000 in Adjusted EBITDA, marking four out of five positive quarters under current CEO.

• Launched Evome Medical Products Distribution Company to expand into broader Life Science products.

• Appointed Bill Garbarini as COO to drive new product initiatives and margin improvement.

Financial highlights

• Q3 2024 gross margin reached $3.6 million, with $2.4 million from Biodex.

• Adjusted EBITDA for Q3 2024 was $424,000, including $0.7 million from Biodex.

• Debt reduced by $1.4 million in Q3 2024, with a 24% total reduction since June 2023.

• Core business Biodex saw 7% gross margin growth over the prior quarter.

Outlook and guidance

• Plans to launch new Biodex-branded products, including spinal care and connected force plates, in 2025.

• Finalizing production for SpaceTek Knee™ and next-gen System 5 isokinetic machine.

• Management expects continued revenue growth and improved product mix with higher-margin products.